USA flag logo/image

An Official Website of the United States Government

THE LONG TERM GOAL IS TO DEVELOP A SAFE AND EFFECTIVE VACCINE FOR GONORRHAE.

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
1357
Program Year/Program:
1984 / SBIR
Agency Tracking Number:
1357
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Immunomed Corpon
5910-g Breckenridge Parkway Tampa, FL 33610
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1984
Title: THE LONG TERM GOAL IS TO DEVELOP A SAFE AND EFFECTIVE VACCINE FOR GONORRHAE.
Agency: HHS
Contract: N/A
Award Amount: $47,982.00
 

Abstract:

THE LONG TERM GOAL IS TO DEVELOP A SAFE AND EFFECTIVE VACCINE FOR GONORRHAE. FIRST, OUR AIM IS TO DEVELOP AN IN VIVO MODEL SYSTEM FOR GONORRHAE. THE EYE OF THE RABBIT, PARTICULARLY AFTER SOME FORM OF TRAUMTIZATION, IS REPORTED TO BE SUSCEPTIBLE TO INFECTION AND IS OUR PROPOSED MODEL SYSTEM. SECOND, IS TO CHARACTERIZE THE IMMUNE RESPONSE TO THE PILAR COMMON ANTIGENIC DETERMINANT. IN THIS PART OF THE STUDY THE PRODUCTION OF DIFFERENT CLASS IMMUNOGLOBINS WILL BE ACHIEVED, REASONING THAT THE PRODUCTION OF SECRETORY IMMUNOGLOBINS SHOULD BE MOST PROTECTIVE MECHANISM. THIRD, WILL BE TO DETERMINE THE PROTECTIVE EFFECT OF THE PILAR COMMON ANTIGEN AGAINST VIRULENT N. GONORRHAEAE WITH DIFFERENT SEROTYPES OF PILI. THIS WILL BE CARRIED OUT AFTER THE DEVELOPMENT OF THE IN VIVO ANIMAL MODEL. NEXT, THE COMMON ANTIGENIC STRUCTURES OF N. GONORRHAEAE WILL BE ANALYZED AND IN THE CASE OF THE PILAR COMMON ANTIGENIC SITES THE PARTICULAR AMINO ACID SEQUENCE WILL BE INVESTIGATED FOR PROTECTIVE ACTIVITY. THIS PROJECT WOULD BE A PRELUDE TO ACTUAL TESTING OF A PILI SUBUNIT VACCINE IN HUMANS.

Principal Investigator:

John c. mcmichael
SENIOR SCIENTIST
0

Business Contact:

Small Business Information at Submission:

Immunomed Corpon
4904 West Cypress Street Tampa, FL 33607

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No